back to cluster viewer
cluster path 00011010110
162 words, 13,676 tokens
freq alpha suffix
Words in frequency order
1 | consisted | 6,930
|
2 | consisting | 3,776
|
3 | consists | 2,100
|
4 | consist | 656
|
5 | .none | 14
|
6 | trial/epidemiology | 13
|
7 | -effectiveness | 7
|
8 | /epidemiology | 7
|
9 | .rates | 3
|
10 | -chemosensitization | 2
|
11 | .analysis | 2
|
12 | .because | 2
|
13 | .date | 2
|
14 | .dates | 2
|
15 | .limitations | 2
|
16 | .many | 2
|
17 | .numbers | 2
|
18 | .quality | 2
|
19 | .risk | 2
|
20 | .risks | 2
|
21 | .use | 2
|
22 | /fraction | 2
|
23 | 35cc | 2
|
24 | f-fluorination | 2
|
25 | noninducibility | 2
|
26 | post-end | 2
|
27 | 'strengthening | 1
|
28 | ,2.predictors | 1
|
29 | -abdomen | 1
|
30 | -dependence | 1
|
31 | -functionality | 1
|
32 | -gains | 1
|
33 | -markers | 1
|
34 | -mixtures | 1
|
35 | -properties | 1
|
36 | -s-conjugate | 1
|
37 | -sides | 1
|
38 | -stun-killing | 1
|
39 | -subtypes | 1
|
40 | -utilisation | 1
|
41 | -utilization | 1
|
42 | -whichever | 1
|
43 | -x-x-met | 1
|
44 | .carcinoma | 1
|
45 | .comparisons | 1
|
46 | .concentrations | 1
|
47 | .level | 1
|
48 | .out | 1
|
49 | .pooling | 1
|
50 | .prevalence | 1
|
51 | .re-analysis | 1
|
52 | .susceptibility | 1
|
53 | .values | 1
|
54 | .variability | 1
|
55 | .variations | 1
|
56 | /hpf | 1
|
57 | /inhibitor | 1
|
58 | /oxygenation | 1
|
59 | /pattern | 1
|
60 | /septicemia | 1
|
61 | /suppressors | 1
|
62 | /time-to-loss | 1
|
63 | 1-application | 1
|
64 | 1-effect | 1
|
65 | 14⩽number | 1
|
66 | 15-hydroxylation | 1
|
67 | 18,812 | 1
|
68 | 2-effect | 1
|
69 | 200-units | 1
|
70 | 2a=comparison | 1
|
71 | 2μgm/kg | 1
|
72 | 3-effect | 1
|
73 | 300-units | 1
|
74 | 4-effect | 1
|
75 | 40-70years | 1
|
76 | 5-effect | 1
|
77 | 70/90 | 1
|
78 | acdification | 1
|
79 | amidolithiation | 1
|
80 | astate | 1
|
81 | attended/number | 1
|
82 | bacilli/kg | 1
|
83 | bioherms | 1
|
84 | c-measurement | 1
|
85 | ca-salts | 1
|
86 | cap-fulls | 1
|
87 | circulares | 1
|
88 | clients'perceptions | 1
|
89 | co-decoction | 1
|
90 | components.effectiveness | 1
|
91 | consortium-association | 1
|
92 | cut-scores | 1
|
93 | d'action | 1
|
94 | database/database | 1
|
95 | de-acetylation | 1
|
96 | decoating | 1
|
97 | depth/length | 1
|
98 | detachment/death | 1
|
99 | disease.treatment | 1
|
100 | domowych | 1
|
101 | eiso-treatment | 1
|
102 | encasement | 1
|
103 | end-stacking | 1
|
104 | eye-line | 1
|
105 | f6-3 | 1
|
106 | failure/lack | 1
|
107 | fibrate-type | 1
|
108 | fluorescent-labeling | 1
|
109 | forcement | 1
|
110 | ga-radiolabeling | 1
|
111 | germinations | 1
|
112 | group-consisted | 1
|
113 | group.none | 1
|
114 | group/risk | 1
|
115 | h-43 | 1
|
116 | heatpenetration | 1
|
117 | i-x | 1
|
118 | induced-injury | 1
|
119 | infection.searches | 1
|
120 | loopful | 1
|
121 | metal-doping | 1
|
122 | metrictons | 1
|
123 | mgo-modification | 1
|
124 | mitogenomes | 1
|
125 | mtd/rp2d | 1
|
126 | ne30d/l30d55 | 1
|
127 | nhbn | 1
|
128 | ofhgl | 1
|
129 | onlevels | 1
|
130 | p213 | 1
|
131 | paleofloras | 1
|
132 | per/g | 1
|
133 | phosphoglycoproteins | 1
|
134 | pl/t | 1
|
135 | plan/style | 1
|
136 | planarization | 1
|
137 | pyrrolidinecarboxamides | 1
|
138 | raphides | 1
|
139 | redox-pair | 1
|
140 | resin-infiltration | 1
|
141 | rv1454c | 1
|
142 | scheduling/availability | 1
|
143 | self-cleavage | 1
|
144 | self-sensitization | 1
|
145 | self-theories | 1
|
146 | sociometry | 1
|
147 | studies-2 | 1
|
148 | study.measurement | 1
|
149 | subcommand | 1
|
150 | syn-conformer | 1
|
151 | tcid50/g | 1
|
152 | titration/permutation | 1
|
153 | to/facilitators | 1
|
154 | translocase/cluster | 1
|
155 | type/dosage/route | 1
|
156 | violations.none | 1
|
157 | vp/dose | 1
|
158 | yang-weakness | 1
|
159 | yin-weakness | 1
|
160 | ×100/s | 1
|
161 | δsubunit | 1
|
162 | ⟩ | 1
|
Words in alphabetical order
1 | 'strengthening | 1
|
2 | ,2.predictors | 1
|
3 | -abdomen | 1
|
4 | -chemosensitization | 2
|
5 | -dependence | 1
|
6 | -effectiveness | 7
|
7 | -functionality | 1
|
8 | -gains | 1
|
9 | -markers | 1
|
10 | -mixtures | 1
|
11 | -properties | 1
|
12 | -s-conjugate | 1
|
13 | -sides | 1
|
14 | -stun-killing | 1
|
15 | -subtypes | 1
|
16 | -utilisation | 1
|
17 | -utilization | 1
|
18 | -whichever | 1
|
19 | -x-x-met | 1
|
20 | .analysis | 2
|
21 | .because | 2
|
22 | .carcinoma | 1
|
23 | .comparisons | 1
|
24 | .concentrations | 1
|
25 | .date | 2
|
26 | .dates | 2
|
27 | .level | 1
|
28 | .limitations | 2
|
29 | .many | 2
|
30 | .none | 14
|
31 | .numbers | 2
|
32 | .out | 1
|
33 | .pooling | 1
|
34 | .prevalence | 1
|
35 | .quality | 2
|
36 | .rates | 3
|
37 | .re-analysis | 1
|
38 | .risk | 2
|
39 | .risks | 2
|
40 | .susceptibility | 1
|
41 | .use | 2
|
42 | .values | 1
|
43 | .variability | 1
|
44 | .variations | 1
|
45 | /epidemiology | 7
|
46 | /fraction | 2
|
47 | /hpf | 1
|
48 | /inhibitor | 1
|
49 | /oxygenation | 1
|
50 | /pattern | 1
|
51 | /septicemia | 1
|
52 | /suppressors | 1
|
53 | /time-to-loss | 1
|
54 | 1-application | 1
|
55 | 1-effect | 1
|
56 | 14⩽number | 1
|
57 | 15-hydroxylation | 1
|
58 | 18,812 | 1
|
59 | 2-effect | 1
|
60 | 200-units | 1
|
61 | 2a=comparison | 1
|
62 | 2μgm/kg | 1
|
63 | 3-effect | 1
|
64 | 300-units | 1
|
65 | 35cc | 2
|
66 | 4-effect | 1
|
67 | 40-70years | 1
|
68 | 5-effect | 1
|
69 | 70/90 | 1
|
70 | acdification | 1
|
71 | amidolithiation | 1
|
72 | astate | 1
|
73 | attended/number | 1
|
74 | bacilli/kg | 1
|
75 | bioherms | 1
|
76 | c-measurement | 1
|
77 | ca-salts | 1
|
78 | cap-fulls | 1
|
79 | circulares | 1
|
80 | clients'perceptions | 1
|
81 | co-decoction | 1
|
82 | components.effectiveness | 1
|
83 | consist | 656
|
84 | consisted | 6,930
|
85 | consisting | 3,776
|
86 | consists | 2,100
|
87 | consortium-association | 1
|
88 | cut-scores | 1
|
89 | d'action | 1
|
90 | database/database | 1
|
91 | de-acetylation | 1
|
92 | decoating | 1
|
93 | depth/length | 1
|
94 | detachment/death | 1
|
95 | disease.treatment | 1
|
96 | domowych | 1
|
97 | eiso-treatment | 1
|
98 | encasement | 1
|
99 | end-stacking | 1
|
100 | eye-line | 1
|
101 | f-fluorination | 2
|
102 | f6-3 | 1
|
103 | failure/lack | 1
|
104 | fibrate-type | 1
|
105 | fluorescent-labeling | 1
|
106 | forcement | 1
|
107 | ga-radiolabeling | 1
|
108 | germinations | 1
|
109 | group-consisted | 1
|
110 | group.none | 1
|
111 | group/risk | 1
|
112 | h-43 | 1
|
113 | heatpenetration | 1
|
114 | i-x | 1
|
115 | induced-injury | 1
|
116 | infection.searches | 1
|
117 | loopful | 1
|
118 | metal-doping | 1
|
119 | metrictons | 1
|
120 | mgo-modification | 1
|
121 | mitogenomes | 1
|
122 | mtd/rp2d | 1
|
123 | ne30d/l30d55 | 1
|
124 | nhbn | 1
|
125 | noninducibility | 2
|
126 | ofhgl | 1
|
127 | onlevels | 1
|
128 | p213 | 1
|
129 | paleofloras | 1
|
130 | per/g | 1
|
131 | phosphoglycoproteins | 1
|
132 | pl/t | 1
|
133 | plan/style | 1
|
134 | planarization | 1
|
135 | post-end | 2
|
136 | pyrrolidinecarboxamides | 1
|
137 | raphides | 1
|
138 | redox-pair | 1
|
139 | resin-infiltration | 1
|
140 | rv1454c | 1
|
141 | scheduling/availability | 1
|
142 | self-cleavage | 1
|
143 | self-sensitization | 1
|
144 | self-theories | 1
|
145 | sociometry | 1
|
146 | studies-2 | 1
|
147 | study.measurement | 1
|
148 | subcommand | 1
|
149 | syn-conformer | 1
|
150 | tcid50/g | 1
|
151 | titration/permutation | 1
|
152 | to/facilitators | 1
|
153 | translocase/cluster | 1
|
154 | trial/epidemiology | 13
|
155 | type/dosage/route | 1
|
156 | violations.none | 1
|
157 | vp/dose | 1
|
158 | yang-weakness | 1
|
159 | yin-weakness | 1
|
160 | ×100/s | 1
|
161 | δsubunit | 1
|
162 | ⟩ | 1
|
Words in suffix order
1 | 70/90 | 1
|
2 | studies-2 | 1
|
3 | 18,812 | 1
|
4 | f6-3 | 1
|
5 | p213 | 1
|
6 | h-43 | 1
|
7 | ne30d/l30d55 | 1
|
8 | /septicemia | 1
|
9 | .carcinoma | 1
|
10 | rv1454c | 1
|
11 | 35cc | 2
|
12 | mtd/rp2d | 1
|
13 | consisted | 6,930
|
14 | group-consisted | 1
|
15 | subcommand | 1
|
16 | post-end | 2
|
17 | -dependence | 1
|
18 | .prevalence | 1
|
19 | self-cleavage | 1
|
20 | plan/style | 1
|
21 | eye-line | 1
|
22 | .none | 14
|
23 | group.none | 1
|
24 | violations.none | 1
|
25 | fibrate-type | 1
|
26 | database/database | 1
|
27 | vp/dose | 1
|
28 | .use | 2
|
29 | .because | 2
|
30 | .date | 2
|
31 | -s-conjugate | 1
|
32 | astate | 1
|
33 | type/dosage/route | 1
|
34 | /hpf | 1
|
35 | tcid50/g | 1
|
36 | per/g | 1
|
37 | bacilli/kg | 1
|
38 | 2μgm/kg | 1
|
39 | end-stacking | 1
|
40 | fluorescent-labeling | 1
|
41 | ga-radiolabeling | 1
|
42 | -stun-killing | 1
|
43 | .pooling | 1
|
44 | 'strengthening | 1
|
45 | metal-doping | 1
|
46 | decoating | 1
|
47 | consisting | 3,776
|
48 | domowych | 1
|
49 | detachment/death | 1
|
50 | depth/length | 1
|
51 | failure/lack | 1
|
52 | .risk | 2
|
53 | group/risk | 1
|
54 | .level | 1
|
55 | ofhgl | 1
|
56 | loopful | 1
|
57 | nhbn | 1
|
58 | -abdomen | 1
|
59 | acdification | 1
|
60 | mgo-modification | 1
|
61 | 1-application | 1
|
62 | consortium-association | 1
|
63 | amidolithiation | 1
|
64 | de-acetylation | 1
|
65 | 15-hydroxylation | 1
|
66 | /oxygenation | 1
|
67 | f-fluorination | 2
|
68 | heatpenetration | 1
|
69 | resin-infiltration | 1
|
70 | -utilisation | 1
|
71 | titration/permutation | 1
|
72 | -utilization | 1
|
73 | planarization | 1
|
74 | self-sensitization | 1
|
75 | -chemosensitization | 2
|
76 | d'action | 1
|
77 | /fraction | 2
|
78 | co-decoction | 1
|
79 | 2a=comparison | 1
|
80 | /pattern | 1
|
81 | attended/number | 1
|
82 | 14⩽number | 1
|
83 | syn-conformer | 1
|
84 | translocase/cluster | 1
|
85 | -whichever | 1
|
86 | redox-pair | 1
|
87 | /inhibitor | 1
|
88 | ×100/s | 1
|
89 | paleofloras | 1
|
90 | raphides | 1
|
91 | pyrrolidinecarboxamides | 1
|
92 | -sides | 1
|
93 | infection.searches | 1
|
94 | self-theories | 1
|
95 | -properties | 1
|
96 | mitogenomes | 1
|
97 | -subtypes | 1
|
98 | circulares | 1
|
99 | cut-scores | 1
|
100 | -mixtures | 1
|
101 | .dates | 2
|
102 | .rates | 3
|
103 | .values | 1
|
104 | .re-analysis | 1
|
105 | .analysis | 2
|
106 | .risks | 2
|
107 | onlevels | 1
|
108 | cap-fulls | 1
|
109 | bioherms | 1
|
110 | -gains | 1
|
111 | phosphoglycoproteins | 1
|
112 | .variations | 1
|
113 | germinations | 1
|
114 | .concentrations | 1
|
115 | .limitations | 2
|
116 | clients'perceptions | 1
|
117 | .comparisons | 1
|
118 | metrictons | 1
|
119 | 40-70years | 1
|
120 | .numbers | 2
|
121 | -markers | 1
|
122 | /suppressors | 1
|
123 | to/facilitators | 1
|
124 | ,2.predictors | 1
|
125 | -effectiveness | 7
|
126 | components.effectiveness | 1
|
127 | yang-weakness | 1
|
128 | yin-weakness | 1
|
129 | /time-to-loss | 1
|
130 | 200-units | 1
|
131 | 300-units | 1
|
132 | ca-salts | 1
|
133 | consists | 2,100
|
134 | pl/t | 1
|
135 | 1-effect | 1
|
136 | 2-effect | 1
|
137 | 3-effect | 1
|
138 | 4-effect | 1
|
139 | 5-effect | 1
|
140 | -x-x-met | 1
|
141 | δsubunit | 1
|
142 | forcement | 1
|
143 | c-measurement | 1
|
144 | study.measurement | 1
|
145 | encasement | 1
|
146 | eiso-treatment | 1
|
147 | disease.treatment | 1
|
148 | consist | 656
|
149 | .out | 1
|
150 | i-x | 1
|
151 | /epidemiology | 7
|
152 | trial/epidemiology | 13
|
153 | .many | 2
|
154 | sociometry | 1
|
155 | induced-injury | 1
|
156 | -functionality | 1
|
157 | .quality | 2
|
158 | .variability | 1
|
159 | scheduling/availability | 1
|
160 | noninducibility | 2
|
161 | .susceptibility | 1
|
162 | ⟩ | 1
|